Key facts
- It has raised $181.2M across 3 recorded rounds; the latest was Later Stage VC ($62.5M) in Mar 2022.
- Notable investors include 8VC, Alexandria Venture Investments, Olive Tree Capital, Mission BioCapital, Revelation Partners — 17 tracked in total.
- Dren Bio has filed 4 Form Ds with the SEC since 2019, most recently Mar 2022 ($62.5M sold to 27 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Dren Bio
Funding rounds
3 roundsAbout Dren Bio
Developer of a biotechnology platform intended to develop protein-based technologies to deplete pathogenic cells and agents in numerous diseases. The company's platform focuses on hematologic neoplasms, solid cancers, and other areas including auto-immune disorders and diseases of protein aggregation, enabling healthcare professionals to tackle various deadly diseases in an easy manner.
- Sector
- Healthcare
- HQ
- Foster City, CA, United States
- Founded
- 2019
- Employees
- 50
- Website
- drenbio.com/
- Ownership
- Privately Held (backing)
Dren Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dren Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dren Bio in its N-PORT filings yet. We sweep new filings monthly.